Immuron Ltd Market Cap ($8.09 Million)
Market Cap & Net Worth: Immuron Ltd (IMC)
Immuron Ltd market cap. Immuron Ltd (AU:IMC) has a market capitalization of $8.09 Million (AU$11.43 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #27419 globally and #1320 in its home market, demonstrating a -12.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immuron Ltd's stock price AU$0.04 by its total outstanding shares 326653609 (326.65 Million). Also see Immuron Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Immuron Ltd Market Cap History (2015–2026)
Immuron Ltd market cap history from 2015 to 2026. Data shows change from $112.26 Million to $8.09 Million (-22.11% CAGR). Check IMC live share price for real-time trading data and today's change.
Immuron Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immuron Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IMC net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.14x
Immuron Ltd's market cap is 1.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $62.40 Million | $1.00 Million | -$7.07 Million | 62.34x | N/A |
| 2017 | $43.91 Million | $1.40 Million | -$6.80 Million | 31.45x | N/A |
| 2018 | $46.23 Million | $1.84 Million | -$3.01 Million | 25.08x | N/A |
| 2019 | $30.05 Million | $2.39 Million | -$4.66 Million | 12.59x | N/A |
| 2020 | $53.16 Million | $2.52 Million | -$2.93 Million | 21.11x | N/A |
| 2021 | $23.11 Million | $145.78K | -$8.38 Million | 158.55x | N/A |
| 2022 | $19.88 Million | $765.19K | -$2.85 Million | 25.98x | N/A |
| 2023 | $17.80 Million | $1.80 Million | -$3.79 Million | 9.86x | N/A |
| 2024 | $18.26 Million | $4.90 Million | -$6.94 Million | 3.72x | N/A |
| 2025 | $8.32 Million | $7.29 Million | -$5.22 Million | 1.14x | N/A |
Competitor Companies of IMC by Market Capitalization
Companies near Immuron Ltd in the global market cap rankings as of November 7, 2026. Also see Immuron Ltd assets under control for a full breakdown of the balance sheet.
Key companies related to Immuron Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Immuron Ltd (2015–2026)
Market capitalization of Immuron Ltd from 2015 to today. Between 2015 and today, Immuron Ltd's market cap moved from $112.26 Million to $ 8.09 Million, with a yearly change of -22.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$8.09 Million | -2.78% |
| 2025 | AU$8.32 Million | -54.43% |
| 2024 | AU$18.26 Million | +2.60% |
| 2023 | AU$17.80 Million | -10.47% |
| 2022 | AU$19.88 Million | -14.00% |
| 2021 | AU$23.11 Million | -56.52% |
| 2020 | AU$53.16 Million | +76.92% |
| 2019 | AU$30.05 Million | -35.00% |
| 2018 | AU$46.23 Million | +5.26% |
| 2017 | AU$43.91 Million | -29.63% |
| 2016 | AU$62.40 Million | -44.41% |
| 2015 | AU$112.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Immuron Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.09 Million USD |
| MoneyControl | $8.09 Million USD |
| MarketWatch | $8.09 Million USD |
| marketcap.company | $8.09 Million USD |
| Reuters | $8.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more